Bladder Cancer
June 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Bladder Cancer abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Bladder Cancer. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Bladder Cancer. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Bladder Cancer every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
Authors:Sun F, Zhao R, Zhu Y, Cui D, Wang X, Han B, Liang S, Liu H, Sun X, Zhao F, Xu D, Xia S
Institution:Shanghai General Hospital, Shanghai, China.
Journal:Cancer Chemother Pharmacol. 2017 Jun;79(6):1099-1107. doi: 10.1007/s00280-017-3305-x. Epub 2017 Apr 18.

2:Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
Authors:Khanal A, Budhathoki N, Singh VP, Shah BK
Institution:Section of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A.
Journal:Anticancer Res. 2017 Apr;37(4):2033-2036.

3:Tackling non-muscle invasive bladder cancer in the clinic.
Authors:Woldu SL, Sanli O, Lotan Y
Institution:a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA. Dallas , TX , USA. Istanbul , Turkey. Dallas , TX , USA.
Journal:Expert Rev Anticancer Ther. 2017 May;17(5):467-480. doi: 10.1080/14737140.2017.1313119. Epub 2017 Apr 11.

4:Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients.
Authors:Kasmann L, Manig L, Janssen S, Rades D
Institution:Department of Radiation Oncology, University of Lubeck, Lubeck, Germany. rades.dirk@gmx.net.
Journal:In Vivo. 2017 Mar-Apr;31(2):239-241.

5:Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.
Authors:Aoun F, Rassy EE, Assi T, Albisinni S, Katan J
Institution:Department of Urology, Hotel Dieu de France, Saint Joseph University, Beirut, Lebanon. Belgium. Lebanon. Belgium. Lebanon.
Journal:Immunotherapy. 2017 Mar;9(5):451-460. doi: 10.2217/imt-2017-0007.

6:The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.
Authors:Pietzak EJ
Institution:Division of Urology, Department of Surgery, University of Pennsylvania Health System, 3rd Floor, West Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA, USA. Eugene.Pietzak@gmail.com.
Journal:Curr Urol Rep. 2017 May;18(5):39. doi: 10.1007/s11934-017-0685-8.

7:Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer.
Authors:Sun X, Hoadley KA, Kim WY, Furberg H, Olshan AF, Troester MA
Institution:Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Suite 32, CVS Plaza, 137 East Franklin Street, CB#8050, Chapel Hill, NC, 27599, USA. amysun@email.unc.edu. Hill, Chapel Hill, NC, USA. NC, USA. Hill, Chapel Hill, NC, USA. NC, USA. Carolina at Chapel Hill, Chapel Hill, NC, USA. NC, USA. Center, New York, NY, USA. of North Carolina at Chapel Hill, Suite 32, CVS Plaza, 137 East Franklin Street, CB#8050, Chapel Hill, NC, 27599, USA. Hill, Chapel Hill, NC, USA. of North Carolina at Chapel Hill, Suite 32, CVS Plaza, 137 East Franklin Street, CB#8050, Chapel Hill, NC, 27599, USA. Hill, Chapel Hill, NC, USA.
Journal:Cancer Causes Control. 2017 Jun;28(6):539-544. doi: 10.1007/s10552-017-0885-z. Epub 2017 Mar 20.

8:Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
Authors:Rades D, Manig L, Janssen S, Schild SE
Institution:Department of Radiation Oncology, University of Lubeck, Lubeck, Germany rades.dirk@gmx.net.
Journal:Anticancer Res. 2017 Mar;37(3):1485-1488.

9:Management of Voiding Dysfunction After Female Neobladder Creation.
Authors:Hoy NY, Cohn JA, Kowalik CG, Kaufman MR, Stuart Reynolds W, Dmochowski RR
Institution:Division of Urology, University of Alberta, Edmonton, AB, Canada. Medical Center North, Nashville, TN, 37232, USA. joshua.cohn@vanderbilt.edu. Medical Center North, Nashville, TN, 37232, USA. Medical Center North, Nashville, TN, 37232, USA. Medical Center North, Nashville, TN, 37232, USA. Medical Center North, Nashville, TN, 37232, USA.
Journal:Curr Urol Rep. 2017 May;18(5):33. doi: 10.1007/s11934-017-0682-y.

10:Precision surgery and genitourinary cancers.
Authors:Autorino R, Porpiglia F, Dasgupta P, Rassweiler J, Catto JW, Hampton LJ, Lima E, Mirone V, Derweesh IH, Debruyne FMJ
Institution:Urology Institute, University Hospitals, Case Western Reserve University, Cleveland, OH, USA. Electronic address: ricautor@gmail.com. Electronic address: porpiglia@libero.it. prokarurol@gmail.com. Heidelberg, Germany. Electronic address: jens.rassweiler@slk-kliniken.de. address: j.catto@sheffield.ac.uk. Electronic address: lance.hampton@vcuhealth.org. University of Minho, and Department of CUF Urology, Braga, Portugal. Electronic address: estevaolima@ecsaude.uminho.pt. mirone@unina.it. address: iderweesh@gmail.com. f.debruyne@uroweb.org.
Journal:Eur J Surg Oncol. 2017 May;43(5):893-908. doi: 10.1016/j.ejso.2017.02.005. Epub 2017 Feb 20.

11:Effects of Vitamin and Antioxidant Supplements in Prevention of Bladder Cancer: a Meta-Analysis of Randomized Controlled Trials.
Authors:Park SJ, Myung SK, Lee Y, Lee YJ
Institution:Department of Family Medicine, National Cancer Center, Goyang, Korea. Policy, National Cancer Center, Goyang, Korea. Research Institute, National Cancer Center, Goyang, Korea. Goyang, Korea. msk@ncc.re.kr. Severance Hospital, Seoul, Korea.
Journal:J Korean Med Sci. 2017 Apr;32(4):628-635. doi: 10.3346/jkms.2017.32.4.628.

12:Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guerin.
Authors:Packiam VT, Johnson SC, Steinberg GD
Institution:Section of Urology, Department of Surgery, University of Chicago Medical Center, Chicago, Illinois. Chicago, Illinois. Chicago, Illinois.
Journal:Cancer. 2017 Feb 1;123(3):390-400. doi: 10.1002/cncr.30392. Epub 2016 Nov 2.

13:VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
Authors:Hussain SA, Ansari J, Huddart R, Power DG, Lyons J, Wylie J, Vilarino-Varlela M, Elander NO, McMenemin R, Pickering LM, Faust G, Chauhan S, Jackson RJ
Institution:University of Liverpool, Liverpool L69 3GA, UK. UK. Tyne NE7 7DN, UK.
Journal:Int J Oncol. 2017 Mar;50(3):768-772. doi: 10.3892/ijo.2017.3847. Epub 2017 Jan 13.

14:Guideline of guidelines: non-muscle-invasive bladder cancer.
Authors:Woldu SL, Bagrodia A, Lotan Y
Institution:Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. TX, USA. TX, USA.
Journal:BJU Int. 2017 Mar;119(3):371-380. doi: 10.1111/bju.13760. Epub 2017 Jan 24.

15:Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
Authors:Patel R, Bock M, Polotti CF, Elsamra S
Institution:a Division of Urology , Rutgers Robert Wood Johnson Medical School , New Brunswick , NJ , USA. Brunswick , NJ , USA. Brunswick , NJ , USA. Brunswick , NJ , USA. Robert Wood Johnson Medical School , New Brunswick , NJ , USA.
Journal:Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):225-232. doi: 10.1080/17425255.2017.1277204. Epub 2017 Jan 11.

16:Occupational exposure to solvents and bladder cancer: A population-based case control study in Nordic countries.
Authors:Hadkhale K, Martinsen JI, Weiderpass E, Kjaerheim K, Sparen P, Tryggvadottir L, Lynge E, Pukkala E
Institution:Department of Epidemiology, University of Tampere, Tampere, Finland. Cancer Research, Oslo, Norway. Cancer Research, Oslo, Norway. Tromso, The Arctic University of Norway, Tromso, Norway. Stockholm, Sweden. Cancer Research, Oslo, Norway. Stockholm, Sweden. Copenhagen, Copenhagen, Denmark. Research, Helsinki, Finland.
Journal:Int J Cancer. 2017 Apr 15;140(8):1736-1746. doi: 10.1002/ijc.30593. Epub 2017 Jan 19.

17:A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.
Authors:Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, Minami K, Enomoto Y, Nasu T, Yoshida T, Fuse H, Hara I, Kawaguchi K, Arimura A, Fujioka T
Institution:Department of Urology, Iwate medical University School of Medicine, Morioka. Sciences, Nagoya. University of Medicine, Kyoto. for Research, University of Toyama, Toyama.
Journal:Ann Oncol. 2017 Apr 1;28(4):798-803. doi: 10.1093/annonc/mdw675.

18:The feasibility and effectiveness of robot-assisted radical cystectomy after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.
Authors:Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Yamauchi A, Shimazui T, Ohtani M
Institution:Department of Urology, Hirosaki University Graduate School of Medicine, Aomori. Medicine, University of Tsukuba, Japan.
Journal:Jpn J Clin Oncol. 2017 Mar 1;47(3):252-256. doi: 10.1093/jjco/hyw191.

19:Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
Authors:Funt SA, Rosenberg JE
Institution:Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA. New York, New York 10065, USA.
Journal:Nat Rev Clin Oncol. 2017 Apr;14(4):221-234. doi: 10.1038/nrclinonc.2016.188. Epub 2016 Nov 22.

20:Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study.
Authors:Kamiya N, Suzuki H, Suyama T, Kobayashi M, Fukasawa S, Sekita N, Mikami K, Nihei N, Naya Y, Ichikawa T
Institution:Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan. naoto.kamiya@med.toho-u.ac.jp. Sakura, Chiba, 285-8741, Japan. Ichihara, Chiba, 299-0111, Japan. 260-8717, Japan. 260-8717, Japan. Narashino, Chiba, 275-8580, Japan. Narashino, Chiba, 275-8580, Japan. Inohana, Chuo-ku, Chiba, 260-8670, Japan. Ichihara, Chiba, 299-0111, Japan. Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Journal:Int J Clin Oncol. 2017 Apr;22(2):353-358. doi: 10.1007/s10147-016-1048-z. Epub 2016 Oct 15.

21:Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer.
Authors:Takaoka EI, Miyazaki J, Ishikawa H, Kawai K, Kimura T, Ishitsuka R, Kojima T, Kanuma R, Takizawa D, Okumura T, Sakurai H, Nishiyama H
Institution:Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba. Tsukuba, Japan. Tsukuba, Japan. Tsukuba, Japan. Tsukuba, Japan. Tsukuba, Japan. nishiuro@md.tsukuba.ac.jp.
Journal:Jpn J Clin Oncol. 2017 Jan;47(1):67-73. doi: 10.1093/jjco/hyw151. Epub 2016 Oct 13.

22:The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience.
Authors:Moschini M, Luzzago S, Zaffuto E, Dell'Oglio P, Gandaglia G, Mattei A, Damiano R, Soria F, Klatte T, Shariat SF, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R
Institution:Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI, Milan, Italy; Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: marco.moschini87@gmail.com. Italy. Italy. Italy. Italy. Italy. Italy. Italy. Italy. Italy.
Journal:Eur J Surg Oncol. 2017 Apr;43(4):808-814. doi: 10.1016/j.ejso.2016.08.024. Epub 2016 Sep 28.

23:Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.
Authors:Alayev A, Salamon RS, Schwartz NS, Berman AY, Wiener SL, Holz MK
Institution:Department of Biology, Yeshiva University, New York, New York. Einstein College of Medicine, Bronx, New York. mholz@yu.edu.
Journal:J Cell Physiol. 2017 Feb;232(2):436-446. doi: 10.1002/jcp.25443. Epub 2016 Jun 10.

24:Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy.
Authors:Golombos DM, O'Malley P, Lewicki P, Stone BV, Scherr DS
Institution:Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA. Hospital, New York, NY, USA. Hospital, New York, NY, USA. Hospital, New York, NY, USA. Hospital, New York, NY, USA.
Journal:BJU Int. 2017 Jan;119(1):128-134. doi: 10.1111/bju.13535. Epub 2016 Jun 15.

25:Efficacy and safety of late-course hypofractionated radiation therapy for muscle-invasive bladder carcinoma after bladder-conserving surgery.
Authors:Song YP, Ma JB, Wang L, Chen EC, Liu P, Ma Z, Zang RK, Yu JM
Institution:Department of Oncology, Tianjin Medical University, Tianjin, China. Medicine, Qingdao University, Yantai, China. Medicine, Qingdao University, Yantai, China. University, Yantai, China. Medicine, Qingdao University, Yantai, China. Medicine, Qingdao University, Yantai, China. Medicine, Qingdao University, Yantai, China. Medicine, Qingdao University, Yantai, China. China.
Journal:Asia Pac J Clin Oncol. 2017 Apr;13(2):e111-e116. doi: 10.1111/ajco.12351. Epub 2015 Apr 14.

For a FREE PREVIEW of the Medifocus Guidebook on Bladder Cancer click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Bladder Cancer click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Bladder Cancer...
at a Special 20% Discount


Medifocus Guidebook on Bladder Cancer

Updated: June 20, 2017
167 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Bladder Cancer is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

BC92540918

Coupon Expires: August 25, 2017



What Our Customers Are Saying...

"My father, a veterinarian, was recently diagnosed with invasive bladder cancer. In wondering how best to support him, I decided to gift him a copy of the MediFocus Guidebook on Bladder Cancer. I knew it would appeal to his "scientific side". I wrote a loving and personal message in the Guide to remind him how much I loved him and then gave it to him. After reading the Guide, he took it to his Urologist and was able to generate excellent and candid questions about his condition."
R.R.
Modesto, California


"This Medifocus Guidebook was significantly helpful at a time that we needed information quickly. We felt we gained information that offered us insight on what to ask our physician, as well as a preview of options on treatment and risk factors that he would probably discuss with us. Emotionally, it's a 'god-send' to look up and receive information immediately. Thanks."
L.H.S.
Crestview, Florida



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.